KIMBERLY OPPMAN: Open Payments
NPI 1265507487 · HIGHLAND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,621 in 52 payments from 11 companies in 2025. Trend: 2023 $1,007 · 2024 $1,328 · 2025 $1,621
Food & beverage: $1,621
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 23 | $634 |
| Gilead Sciences, Inc. | 8 | $281 |
| ABBVIE INC. | 4 | $187 |
| Paratek Pharmaceuticals, Inc. | 5 | $180 |
| Melinta Therapeutics, LLC | 3 | $146 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| Theratechnologies Inc. | 2 | $41 |
| EMD Serono, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $22 |
Products named: DOVATO, CABENUVA, NUZYRA, EMBLAVEO, Rezzayo, VOWST, MAVYRET, APRETUDE.
Industry payments across IN — which companies pay providers there.
